bluebird bio Announces Participation in Upcoming Investor Conferences

ROTH Conference 2015
Cowen Health Care Conference 2015

CAMBRIDGE, Mass.--()--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:

  • 35th Annual Cowen and Company Health Care Conference on Tuesday, March 3, 2015 at 11:20 a.m. EST at the Boston Marriott Copley Place in Boston.
  • 27th Annual ROTH Conference on Tuesday, March 10, 2015 at 10:30 a.m. PST at the Ritz-Carlton in Dana Point, Calif.

To access the live webcasts of bluebird bio’s presentations, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of each webcast will be available on the bluebird bio website for 90 days following each conference.

About bluebird bio, Inc.

With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical programs include Lenti-D, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in France (HGB-205) for the treatment of beta-thalassemia major or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206). bluebird bio also has a preclinical CAR T cancer immunotherapy program in collaboration with Celgene Corporation, as well as discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies.

bluebird bio has operations in Cambridge, Massachusetts, Seattle, Washington, and Paris, France. For more information, please visit www.bluebirdbio.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of, and anticipated milestones related to the Company’s product candidates. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, the risk of a delay in the enrollment of patients in the Company’s clinical studies, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaboration with Celgene will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Contacts

Investor Relations
bluebird bio, Inc.
Jim DeTore,339-499-9355
Chief Financial Officer
or
Media Contact
Pure Communications, Inc.
Dan Budwick, 973-271-6085

Release Summary

bluebird bio Announces Participation in Upcoming Investor Conferences

Contacts

Investor Relations
bluebird bio, Inc.
Jim DeTore,339-499-9355
Chief Financial Officer
or
Media Contact
Pure Communications, Inc.
Dan Budwick, 973-271-6085